Jasper Therapeutics is a biotechnology company focused on enabling safer conditioning and therapeutic agents that expand the application of curative hematopoietic stem cell transplants and gene therapies. Jasper Therapeutics' lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem cell transplant.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/09/19 | $35,000,000 | Series A |
Abingworth Alexandria Venture Investments Qiming Venture Partners Surveyor Capital | undisclosed |
